Impact of Dialysis Modality on Hepcidin and Iron Metabolism

Inclusion Criteria: * Written informed consent * Age 18 years or older * Dialysis treatment was expected over 3 months * In HD patients, regular hemodialysis 4 h a session more than two times a week * In PD patients, over 2 exchange with more than 1.5 L solution Exclusion Criteria: * Poorly controlled hypertension, i.e. sitting blood pressure exceeding 180/110 despite medication requiring hospitalization or interruption of ESA treatment * Significant acute or chronic bleeding such as overt gastrointestinal bleeding within the previous 3 months * Active malignant disease (except non-melanoma skin cancer and patients with malignant disease who have been disease-free for at least the 5 previous years are eligible) * Acute infection * Hemolysis * Hemoglobinopathies (e.g. homozygous sickle-cell disease, thalassemia of all types) * Megaloblastic anemia * Platelet count \>500 x 109/L or \<100 x 109/L * Pure red call aplasia * Epileptic seizure during previous 3 months * Women of childbearing potential without effective contraception * Known hypersensitivity to recombinant human erythropoietin, polyethylene glycol * Planned elective surgery during the study period except for cataract surgery or laser photocoagulation * Life expectancy less than 12 month